Lipid-lowering therapies underused for primary CVD prevention

In a cohort of more than 400,000 patients at high risk for CVD requiring primary prevention, less than half were taking appropriately dosed statins and less than 10% were taking nonstatin lipid-lowering therapies, researchers reported.
For an abstract presented at the National Lipid Association Scientific Sessions, Ahmed A. Kolkailah, MD, cardiovascular medicine fellow at the University of Texas Southwestern Medical Center, and colleagues analyzed 412,913 patients (median age, 63 years; 50.4% men) included in the Cerner Real-World Dataset of electronic health records from 90 health systems.

In a cohort of more than 400,000 patients at high risk for CVD requiring primary prevention, less than half were taking appropriately dosed statins and less than 10% were taking nonstatin lipid-lowering therapies, researchers reported.
For an abstract presented at the National Lipid Association Scientific Sessions, Ahmed A. Kolkailah, MD, cardiovascular medicine fellow at the University of Texas Southwestern Medical Center, and colleagues analyzed 412,913 patients (median age, 63 years; 50.4% men) included in the Cerner Real-World Dataset of electronic health records from 90 health systems.